Study Supports The Practice Of Treating Worse-Seeing Eye In AMD Patients

Thursday, April 29, 2010

Comments

Ocular Surgery News

Whether the better-seeing or worse-seeing eye was treated with anti-VEGF therapy during pivotal phase 3 trials did not influence patient-reported improvements in visual function, according to a study.

Full Story

Retina Products and Equipment »

All of the following drugs are FDA approved for the treatment of predominantly classic subfoveal CNV in patients with neovascular AMD except for which one?
1. Pegaptanib sodium (Macugen)
2. Verteporfin (Visudyne PDT)
3. Ranibizumab (Lucentis)
4. Bevacizumab (Avastin)
5. All of the above
Check The Answer

CareCloud Charts For Ophthalmology
Get all of the tools you need to deliver... view product
Smartphone-Based Retinal Screening System
D-EYE, The Modern Day Digital ... view product

View all Featured Products »

Keep up with our latest articles, news and events. Plus, get special offers and more delivered to your inbox.

Like us
on Facebook Follow us
on Twitter

OphthalmologyWeb wants to hear from you. Submit your case studies, clinical pearls, practice management tips, editorial, or other manuscripts.

Learn more about writing for us

AdGlare Leaderboard

Study Supports The Practice Of Treating Worse-Seeing Eye In AMD Patients

Comments

Related Categories

Retina Products and Equipment »

Quick Quiz

All of the following drugs are FDA approved for the treatment of predominantly classic subfoveal CNV in patients with neovascular AMD except for which one?

AdGlare RMR Ad

Featured Products

CareCloud Charts For Ophthalmology

Smartphone-Based Retinal Screening System

Follow OphthalmologyWeb

AdGlare RMR2

Write for Us